News: Merck Deploys Coley’s Vaccine Adjuvant Technology.
Merck & Co. licensed Coley Pharmaceutical Group's VaxImmune™ vaccine adjuvant for incorporation into its own vaccines under development for certain infectious diseases and Alzh
Alzheimers News
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs WELLESLEY, Mass., April 12 Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) today announced ...
Emergent biosolutions
... anthrax vaccine candidates, is comprised of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909 (VaxImmune(R ...
IPO Filings
VaxImmune Vaccine Adjuvants for Cancers and Infectious Diseases. We are partnering VaxImmune, our vaccine adjuvant product candidate, with vaccine companies to boost the ...
CpG 7909: PF 3512676, PF-3512676.
Coley licensed CpG 7909 [VaxImmune] to Chiron Corporation for adjuvant use with Chiron's prophylactic vaccine candidates against infectious diseases in December 2003.
Big Pharma's Leap into Biologics: Bridging both Scientific and ...
Windhover Information Inc. - Health Care Business Intelligence. Delivering essential ... Coley grants VaxImmune license to Merck, Deal 4/2007. Pfizer buys diabetes firm BioRexis, Deal 2/2007
